Meeting
2022 ASCO Annual Meeting
Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).
Authors
Arndt Vogel
Hannover Medical School, Hannover, Germany
Arndt Vogel , Li-Tzong Chen , Aiwu Ruth He , Jin Won Kim , Ming-Huang Chen , Mairead Geraldine McNamara , Satoshi Shimizu , Roopinder Gillmore , Felipe Rey , Hyosung Kim , Julia Xiong , Mallory Makowsky , Nana Rokutanda , Gordon Cohen , Do-Youn Oh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03875235
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4075)
DOI
10.1200/JCO.2022.40.16_suppl.4075
Abstract #
4075
Poster Bd #
63
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study.
First Author: Aiwu He
Poster
2022 ASCO Annual Meeting
Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
First Author: Howard A. Burris III
Poster
2023 ASCO Annual Meeting
Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.
First Author: William Joseph Chapin
Poster
2018 ASCO Annual Meeting
Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT).
First Author: Makoto Ueno